Press release archive 2012

Friday, 14 December 2012
CRESTOR US patent upheld by Court of Appeals for the Federal Circuit AstraZeneca announced today that the Court of Appeals for the Federal Circuit has upheld the decision of the District Court, District of Delaware, finding that the US substance patent protecting CRESTOR (rosuvastatin calcium) (RE37,314 – the ‘314 patent) is valid and enforceable. The defendants may seek a rehearing and/or review by the U.S. Supreme Court. Absent a reversal of this decision, none of the Abbreviated New Drug Applications (ANDAs) filed by Apotex, Aurobindo, Cobalt, Glenmark, Mylan, Par, Sandoz, Sun, Teva and Torrent may be approved by the FDA prior to expiration of the ‘314 patent. The ‘314 patent, which expires in 2016, covers rosuvastatin calcium, the active ingredient in CRESTOR.
Thursday, 13 December 2012
AstraZeneca announces top-line results of OSKIRA-4 Phase IIb study of fostamatinib as a monotherapy for rheumatoid arthritis AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis.
Tuesday, 11 December 2012
AstraZeneca and Isis Pharmaceuticals form strategic alliance on RNA therapeutics for cancer AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets.
Wednesday, 14 November 2012
FORXIGA™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU). FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes. This is the first medicine in the new SGLT2 class to gain regulatory approval for the treatment of type 2 diabetes, a disease in which high unmet medical need exists.
Tuesday, 13 November 2012
Court in Germany finds SEROQUEL XR® formulation patent invalid AstraZeneca today announced that the Federal Patent Court in Germany has found the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets – marketed as SEROQUEL Prolong in Germany – to be invalid. The patent was challenged by Accord Healthcare Limited, Hexal AG and TEVA Deutschland GmbH.
Monday, 12 November 2012
AstraZeneca announces top-line phase III results from naloxegol pivotal trials in patients with opioid-induced constipation AstraZeneca today announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC).
Monday, 12 November 2012
Definition of Core Financial Measures Definition of Core Financial Measures will change with effect from Q1 2013.
Wednesday, 31 October 2012
Alzheimer’s, cancer and rare disease research to benefit from landmark MRC-AstraZeneca compound collaboration The Medical Research Council (MRC) today announces £7 million of funding for 15 research projects awarded through its groundbreaking collaboration with innovative pharmaceutical company AstraZeneca, which gave academic researchers unprecedented access to 22 chemical compounds.
Monday, 29 October 2012
AstraZeneca announces details of Chief Executive Officer Pascal Soriot's remuneration AstraZeneca is today making a regulatory disclosure following the grant of share awards to the company’s new Chief Executive Officer Pascal Soriot in compensation for the forfeiture of long-term incentives from his previous employer.
Thursday, 25 October 2012
AstraZeneca PLC Third quarter and nine months results 2012 As expected, the revenue decline in the third quarter reflected the ongoing effect from the loss of exclusivity on several brands. Continued disciplined management of operating expenses and proceeds from the sale of Nexium OTC rights mitigated the impact of the revenue decline on Core operating profit. Financial targets for full year unchanged.